Warning: session_start(): open(/opt/alt/php74/var/lib/php/session/sess_d99b4f76541dd949dee45fdbcafcc061, O_RDWR) failed: Disk quota exceeded (122) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278

Warning: session_start(): Failed to read session data: files (path: /opt/alt/php74/var/lib/php/session) in /home/useaicwl/public_html/wp-content/themes/mushroomstocks/functions.php on line 278
Biotech Cannabis Company to IPO on National Exchange Soon! - Mushroomstocks | Mushroomstocks
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Biotech Cannabis Company to IPO on National Exchange Soon!

Jul 16, 2015 • 2:12 PM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Investors and financial institutions have been patiently waiting for a cannabis-related company to commence trading on a national exchange like the Nasdaq or New York Stock Exchange. Currently, there are only two cannabis related biotech companies that trade on the Nasdaq. These are GW Pharmaceuticals (GWPH) and INSYS Therapeutics, Inc. (INSY). In the near future, a third cannabis related biotech company will have its initial public offering (IPO) and commence trading on the Nasdaq exchange.  

On June 30th, Zynerba Pharmaceuticals, Inc. filed a registration statement on a Form S-1 which is related to the company’s proposed initial public offering. Zynerba’s registration statement is not yet effective and the number of shares to be offered and the price range for the offering have not yet been determined.

Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies.

Two products in Zynerba’s development pipeline

Zynerba’s development pipeline consists of two preclinical programs studying synthetic cannabinoid therapeutics.

  • THC Pro-Drug Patch – ZYN001: ZYN001 is a pro-drug of THC that enables transdermal delivery via a patch. Zynerba is studying ZYN001 in patients with fibromyalgia and peripheral neuropathic pain. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in the second quarter of 2016.
  • CBD Gel – ZYN002: ZYN002 is the first and only synthetic CBD formulated as a patient-protected permeation-enhanced gel for transdermal delivery. Zynerba is studying ZYN002 in patients with refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in the third quarter of 2015.

In October 2014, Zynerba raised $13 million in funding for the first transdermal cannabinoid therapy. At the time of the capital raise, the company was preparing to initiate Phase 1 clinical studies on ZYN001 and on ZYN002.

Zynerba files registration statement with SEC for its IPO

Zynerba announced that Jefferies LLC and Piper Jaffray & Co. will act as joint book-running managers for the offering. Canaccord Genuity and Oppenheimer & Co. will act as co-managers for the offering.

The offering will be made only by means of a prospectus. When available, a copy of the prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com, or by accessing the SEC’s website at www.sec.gov.


We expect Zynerba’s IPO to be a profitable investment due to the strong demand for cannabis related investments from investors and financial institutions. Even though there are more than 300 publicly traded cannabis companies, investors want to invest in companies that trade on a regulated national stock exchange.

Zynerba will fill this need for many investors and we will keep you updated on developments related to its IPO.

To find out more information click here!

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.

Fatal error: Uncaught ErrorException: md5_file(/home/useaicwl/public_html/wp-content/litespeed/css/aa8010291f52a7bf61ff07938d293e92.css.tmp): failed to open stream: No such file or directory in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php:126 Stack trace: #0 [internal function]: litespeed_exception_handler(2, 'md5_file(/home/...', '/home/useaicwl/...', 126, Array) #1 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php(126): md5_file('/home/useaicwl/...') #2 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(797): LiteSpeed\Optimizer->serve('https://mushroo...', 'css', true, Array) #3 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(319): LiteSpeed\Optimize->_build_hash_url(Array) #4 /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimize.cls.php(252): LiteSpeed\Optimize->_optimize() #5 /home/useaicwl/public_html/wp-includes/class-wp-hook.php(310): LiteSpeed\Optimize->f in /home/useaicwl/public_html/wp-content/plugins/litespeed-cache/src/optimizer.cls.php on line 126